Vericel Corporation (NASDAQ: VCEL) reported better-than-expected results in the second quarter aided by strong growth from both of its products. The company
Categories
pharma stocks
Clovis Oncology dips further as loss widens in Q2
Clovis Oncology (NASDAQ: CLVS) on Thursday reported second-quarter results that were weaker than the street expectations. Total revenues rose 39% year-over-year to
Novartis reports better earnings on higher sales in Q2, raises guidance
Swiss pharmaceutical giant Novartis (NYSE: NVS) on Thursday surprised Wall Street by reporting a year-over-year increase in net earnings in Q2, helped
Q2 results will help investors merit Novartis’ strategic transformation
Novartis AG (NYSE: NVS) is scheduled to report second-quarter earnings before the opening bell on Thursday, July 18. The Switzerland-based pharmaceutical giant
AngioDynamics posts in-line EPS of $0.25 in Q4
AngioDynamics (NASDAQ: ANGO) posted fourth-quarter earnings results on Wednesday before the regular trading hours. Net sales for the period increased 9% to $96.3
Neptune Wellness posts wider losses in Q4, shares fall
Canadian producer of wellness products, Neptune Wellness Solutions (NASDAQ: NEPT), said its revenues fell 16% in the first quarter to $5.7 million,
Earnings preview: Advaxis stock treading near an all-time low ahead of Q2 results
Late-stage biotech firm Advaxis, Inc. (NASDAQ: ADXS) is scheduled to report second-quarter financial results on June 10, Monday, after the closing bell.
Solid Biosciences tumbles 38% to hit historic low
Shares of Solid Biosciences Inc. (NASDAQ: SLDB) opened 38% lower on Tuesday after the company said in its first-quarter results that its
InspireMD Q1 revenues plunge on third-party equipment failure
Israel-based medical device company InspireMD (NYSE: NSPR) reported a first-quarter loss of $3.82 per share, much wider than the loss of $2.50
Intercept Pharmaceuticals reports mixed Q1 results
Intercept Pharmaceuticals (NASDAQ: ICPT) reported wider-than-expected losses in the first quarter of 2019, primarily due to higher R&D expenses related to NASH
Earnings: Array BioPharma reports upbeat Q3 results
Array BioPharma (NASDAQ: ARRY) reported a narrower-than-expected loss in the third quarter of 2019, sending its shares up 0.5% during pre-market trading
Wall Street expects a revenue surge from GW Pharmaceuticals in Q1
Medical marijuana company GW Pharmaceuticals (NASDAQ: GWPH) is scheduled to report first-quarter 2019 earnings results on May 6, Monday, after the closing
ImmunoGen reports 57% decline in Q1 revenue
ImmunoGen Inc (NASDAQ: IMGN) on Friday reported weaker-than-expected top line in Q1, as the biotech firm continued to burn money on research
Gilead Sciences tops Q1 earnings estimate, reiterates full-year outlook
Shares of Gilead Sciences (NASDAQ: GILD) gained 1.2% after the biotechnology firm reported first-quarter earnings of $1.76 per share, surpassing the street
ImmunoGen is cheap ahead of Q1 earnings, but is it worth?
ImmunoGen Inc (NASDAQ: IMGN) is one of the worst performing stocks out there, losing about 78% of its value over the course
Gilead Sciences earnings preview: What to expect in Q1
Gilead Sciences (NASDAQ: GILD) has tested its investors enough lately. The stock has increased just 2.5% in the year-to-date period, while its
Amarin Corp tops the market in Q1 on Vascepa strength
Amarin Corporation (NASDAQ: AMRN) on Wednesday said its revenues soared 67% to $73.3 million, riding on the strong demand for its Vascepa
KEYTRUDA helps Merck to report Q1 earnings beat, raises 2019 outlook
Shares of the pharma giant Merck (MRK) rose 2% before the market hours after the company surpassed estimates on the headline numbers.
Amarin earnings preview: Expect higher revenues, but wider losses in Q1
Amarin Corporation (NASDAQ: AMRN) is scheduled to report first-quarter 2019 earnings results on Wednesday, May 1, before the opening bell. Analysts expect the
Cancer drugs boost AstraZeneca results in Q1
Riding on the strong demand for its cancer drugs, AstraZeneca Plc (NYSE: AZN) on Friday reported its third consecutive quarter of top
Bristol-Myers Squibb tops Q1 estimates, gets shareholder approval for Celgene acquisition
Biopharma company Bristol-Myers Squibb (NYSE: BMY) on Thursday reported better-than-expected first-quarter 2019 results, sending its shares up over 1% during pre-market trading.